Crossmark

Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials

Crossref DOI link: https://doi.org/10.1007/s00520-017-3780-y

Published Online: 2017-06-20

Published Print: 2017-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Le-Rademacher, Jennifer

Kanwar, Rahul

Seisler, Drew

Pachman, Deirdre R.

Qin, Rui

Abyzov, Alexej

Ruddy, Kathryn J.

Banck, Michaela S.

Lavoie Smith, Ellen M.

Dorsey, Susan G.

Aaronson, Neil K.

Sloan, Jeff

Loprinzi, Charles L.

Beutler, Andreas S.
Funding

Funding for this research was provided by:

National Institute of Nursing Research (R01NR015259)
License Information

Text and Data Mining valid from 2017-06-20

Version of Record valid from 2017-06-20
More Information

Article History

Received: 28 April 2016

Accepted: 7 June 2017

First Online: 20 June 2017

Compliance with ethical standards

:

: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the Award Number UG1CA189823 (to the Alliance for Clinical Trials in Oncology NCORP Grant) and U10CA180790 and by the National Institute of Nursing Research (NINR) of the National Institutes of Health (NIH) under Award Number R01NR015259 (to A.S.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

: The authors declare that they have no conflicts of interest.

Document is current

Any future updates will be listed below